| Autor: |
Wierda WG; The University of Texas MD Anderson Cancer Center., Byrd JC; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Abramson JS; Massachusetts General Hospital Cancer Center., Bilgrami SF; Yale Cancer Center/Smilow Cancer Hospital., Bociek G; Fred & Pamela Buffett Cancer Center., Brander D; Duke Cancer Institute., Brown J; Dana-Farber/Brigham and Women's Cancer Center., Chanan-Khan AA; Mayo Clinic Cancer Center., Chavez JC; Moffitt Cancer Center., Coutre SE; Stanford Cancer Institute., Davis RS; O'Neal Comprehensive Cancer Center at UAB., Fletcher CD; University of Wisconsin Carbone Cancer Center., Hill B; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic; Taussig Cancer Institute., Kahl BS; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Kamdar M; University of Colorado Cancer Center., Kaplan LD; UCSF Helen Diller Family Comprehensive Cancer Center., Khan N; Fox Chase Cancer Center., Kipps TJ; UC San Diego Moores Cancer Center., Lim MS; Abramson Cancer Center at the University of Pennsylvania., Ma S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Malek S; University of Michigan Rogel Cancer Center., Mato A; Memorial Sloan Kettering Cancer Center., Mosse C; Vanderbilt-Ingram Cancer Center., Shadman M; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance., Siddiqi T; City of Hope National Medical Center., Stephens D; Huntsman Cancer Institute at the University of Utah., Sundaram S; Roswell Park Comprehensive Cancer Center., Wagner N; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and., Dwyer M; National Comprehensive Cancer Network., Sundar H; National Comprehensive Cancer Network. |
| Abstrakt: |
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL. |
